Press Release Headlines

Sanovas Relocating Its International Operations to World-Class "BioTech Ready" Facility in San Rafael, Calif., To Accommodate Its Explosive Growth

SAUSALITO, Calif., April 22, 2014 /PRNewswire/ — Sanovas Inc. (www.sanovas.com), a Life Sciences Accelerator developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that it is relocating its business operations next month to a 29,000-sq.-ft. 'BioTech Ready' facility at 2593 Kerner Blvd., San Rafael, Calif. The relocation is necessary to accommodate the company's planned expansion.

A previous tenant put $5 million into remodeling and improving the facility, and spent an additional $5 million on equipment and technology that will be used immediately by Sanovas. The facility includes R&D development labs, operating rooms, clean rooms, and ample office space, as well as a light-industrial warehouse.

"Our relocation to a world-class 29,000-square-foot 'BioTech Ready' facility will support our aggressive expansion plans," said Larry Gerrans, Co-Founder, President and CEO. "Our new Headquarters will enable us to efficiently drive the evolutionary processes of technology development from concept to commercialization. Sanovas' portfolio of companies are delivering potentially blockbuster minimally invasive surgical products that enable surgeons to access, image, measure, diagnose and treat diseased and obstructed passageways and anatomies in areas of the human body that have been largely inaccessible…until now."

"Our city is the home of many great companies, and we are certainly excited to welcome Sanovas to San Rafael," said Mayor Gary Phillips.

About Sanovas
At the heart of the Sanovas companies' scientific advances is the miniaturization of tools for minimally invasive surgery, or "M-I-S." Its products extend access beyond current limits, enabling physicians to diagnose and perform therapeutic interventions in spaces as small as one millimeter in diameter that have previously been unreachable. Sanovas expects to commercialize the technology in coordination with its various partners to address unmet clinical needs in Oncology, Pulmonology, Cardiology, Neurosurgery, ENT, GI, General Surgery, Urology and Gynecology.